Opinion|Videos|June 27, 2024
Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024.
Advertisement
Episodes in this series
- What current trends are you seeing in the world of breast cancer?How has the treatment of breast cancer evolved in recent history?
- Coming into ASCO 2024, what would you consider to be the largest unmet needs in the treatment and management of breast cancer?
- Provide the key recommendations and updates made in the 2024 NCCN guidelines for breast cancer.
- What have recommendationsfor the treatment and management of breast cancer changed since 2023?
Advertisement
Related to this article
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
Early-Onset Cancers Often Found Late as Screening Gaps Persist
4
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
5